BioCancell, developers of cancer diagnostics, participated in the
MIDC’s MarketReach America™ program. The MIDC introduced
them to physicians at the University of Maryland Medical Center
who conducted clinical trials for BioCancell to submit to the FDA for
approval. BioCancell and the University of Maryland received a BIRD
Foundation grant for the clinical trials.